Isupartob sodium (M6229)
Sepsis / Septic Shock
Phase 1Active
Key Facts
About Matisse Pharmaceuticals
Matisse Pharmaceuticals is a Dutch biotech advancing a novel therapeutic approach to treat life-threatening inflammation, particularly sepsis, by targeting extracellular cytotoxic histones. The company has progressed its lead asset, isupartob sodium, into clinical trials, having recently completed a healthy volunteer study. With a clear mission to save millions of lives, Matisse operates as a private, pre-revenue entity, leveraging strategic partnerships to advance its pipeline in a high-need, underserved market.
View full company profile